Skip to content

A prospective cohort study comparing the safety and survival benefits of inflatable mediastinoscope-assisted transhiatal esophagectomy and definitive chemoradiotherapy in esophageal cancer patient with pulmonary dysfunction

A prospective cohort study comparing the safety and survival benefits of mediastinoscope-assisted transhiatal esophagectomy and definitive chemoradiotherapy in esophageal cancer patient with pulmonary dysfunction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086842
Enrollment
Unknown
Registered
2024-07-11
Start date
2023-05-23
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Exposure group (Inflatable mediastinoscope-assisted transhiatal esophagectomy):None
Non-exposure group (Definitive chemoradiotherapy):None

Sponsors

West China Hospital,Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Age range from 18 to 75 years old, regardless of gender. 2) The pathological diagnosis of gastroscopy is esophageal cancer. 3) Esophageal cancer patients undergoing mediastinal esophagectomy or radical radiotherapy and chemotherapy 4) Severe lung function impairment, meeting any one of FVC = 1.5L, FEV1 < 1.0L, FEV1% = 50%, MVV < 50%, DLCO = 50%, or PaCO2 = 45mmHg, is contraindicated for thoracoscopic surgery. 5) The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.

Exclusion criteria

Exclusion criteria: 1) Patients undergoing palliative resection surgery 2) Patients who have not completed the minimum course of curative radiotherapy and chemotherapy 3) Poor compliance, unwilling to participate in the study or not cooperating with follow-up patients

Design outcomes

Primary

MeasureTime frame
mOS;

Secondary

MeasureTime frame
Postoperative hospitalization duration;Overall Survival;Progressive free survival time;Recurrence-free survival;Quality of life;

Countries

China

Contacts

Public ContactYang Hu

West China Hospital,Sichuan University

huyangthoracic@126.com+86 189 8060 7867

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026